Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 665

1.

Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM.

McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ.

Mol Cancer Ther. 2019 Jul 3. pii: molcanther.1330.2018. doi: 10.1158/1535-7163.MCT-18-1330. [Epub ahead of print]

PMID:
31270152
2.

Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma.

Chandra A, Young JS, Dalle Ore C, Dayani F, Lau D, Wadhwa H, Rick JW, Nguyen AT, McDermott MW, Berger MS, Aghi MK.

J Neurosurg. 2019 Jun 21:1-11. doi: 10.3171/2019.3.JNS182629. [Epub ahead of print]

PMID:
31226687
3.

The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas.

Widhalm G, Olson J, Weller J, Bravo J, Han SJ, Phillips J, Hervey-Jumper SL, Chang SM, Roberts DW, Berger MS.

J Neurosurg. 2019 May 10:1-10. doi: 10.3171/2019.1.JNS182614. [Epub ahead of print]

PMID:
31075771
4.

The management of low-grade gliomas in adults.

Morshed RA, Young JS, Hervey-Jumper SL, Berger MS.

J Neurosurg Sci. 2019 Aug;63(4):450-457. doi: 10.23736/S0390-5616.19.04701-5. Epub 2019 Mar 27.

PMID:
30916536
5.

Delirium Risk Factors and Associated Outcomes in a Neurosurgical Cohort: A Case-Control Study.

Morshed RA, Young JS, Safaee M, Sankaran S, Berger MS, McDermott MW, Hervey-Jumper SL.

World Neurosurg. 2019 Mar 11. pii: S1878-8750(19)30624-2. doi: 10.1016/j.wneu.2019.03.012. [Epub ahead of print]

PMID:
30872201
6.

High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.

Sabelström H, Quigley DA, Fenster T, Foster DJ, Fuchshuber CAM, Saxena S, Yuan E, Li N, Paterno F, Phillips JJ, James CD, Norling B, Berger MS, Persson AI.

Exp Cell Res. 2019 May 1;378(1):76-86. doi: 10.1016/j.yexcr.2019.03.003. Epub 2019 Mar 5.

7.

Roles of ventral versus dorsal pathways in language production: An awake language mapping study.

Ries SK, Piai V, Perry D, Griffin S, Jordan K, Henry R, Knight RT, Berger MS.

Brain Lang. 2019 Apr;191:17-27. doi: 10.1016/j.bandl.2019.01.001. Epub 2019 Feb 12.

PMID:
30769167
8.

Comparing Glioblastoma Surgery Decisions Between Teams Using Brain Maps of Tumor Locations, Biopsies, and Resections.

Müller DMJ, Robe PAJT, Eijgelaar RS, Witte MG, Visser M, de Munck JC, Broekman MLD, Seute T, Hendrikse J, Noske DP, Vandertop WP, Barkhof F, Kouwenhoven MCM, Mandonnet E, Berger MS, De Witt Hamer PC.

JCO Clin Cancer Inform. 2019 Jan;3:1-12. doi: 10.1200/CCI.18.00089.

9.

Erratum. Obituary. Charles B. Wilson, MD, 1929-2018.

Berger MS.

J Neurosurg. 2019 Jan 11;130(3):1022. doi: 10.3171/2018.12.JNS18974a. No abstract available.

PMID:
30641846
10.

Insular glioma surgery: an evolution of thought and practice.

Hervey-Jumper SL, Berger MS.

J Neurosurg. 2019 Jan 1;130(1):9-16. doi: 10.3171/2018.10.JNS181519. Review.

PMID:
30611160
11.

Evaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to Glioblastoma.

Finbloom JA, Aanei IL, Bernard JM, Klass SH, Elledge SK, Han K, Ozawa T, Nicolaides TP, Berger MS, Francis MB.

Nanomaterials (Basel). 2018 Dec 5;8(12). pii: E1007. doi: 10.3390/nano8121007.

12.

MEG imaging of recurrent gliomas reveals functional plasticity of hemispheric language specialization.

Traut T, Sardesh N, Bulubas L, Findlay A, Honma SM, Mizuiri D, Berger MS, Hinkley LB, Nagarajan SS, Tarapore PE.

Hum Brain Mapp. 2019 Mar;40(4):1082-1092. doi: 10.1002/hbm.24430. Epub 2018 Dec 13.

PMID:
30549134
13.

Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.

Morshed RA, Han SJ, Hervey-Jumper SL, Pekmezci M, Troncon I, Chang SM, Butowski NA, Berger MS.

J Neurooncol. 2019 Jan;141(2):383-391. doi: 10.1007/s11060-018-03044-4. Epub 2018 Nov 29.

PMID:
30498891
14.

Obituary. Charles B. Wilson, MD, 1929-2018.

Berger MS, Garner IV, McDermott MW.

J Neurosurg. 2018 Aug 1;129(2):547-550. doi: 10.3171/2018.5.JNS18974. No abstract available. Erratum in: J Neurosurg. 2019 Jan 11;130(3):1022.

PMID:
30485247
15.

Evidence for Improving Outcome Through Extent of Resection.

Hervey-Jumper SL, Berger MS.

Neurosurg Clin N Am. 2019 Jan;30(1):85-93. doi: 10.1016/j.nec.2018.08.005. Epub 2018 Nov 1. Review.

PMID:
30470408
16.

Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Dalle Ore CL, Chandra A, Rick J, Lau D, Shahin M, Nguyen AT, McDermott M, Berger MS, Aghi MK.

Neurosurgery. 2018 Nov 16. doi: 10.1093/neuros/nyy501. [Epub ahead of print]

PMID:
30445646
17.

Commentary: Deficiencies in Socioeconomic Training During Neurosurgical Training.

Karsy M, Park MS, Bekelis K, Braca JA 3rd, Nahed BV, Colen CB, Barbaro NM, Berger MS, Mukherjee D.

Neurosurgery. 2019 Jan 1;84(1):E79-E85. doi: 10.1093/neuros/nyy482. No abstract available.

PMID:
30445444
18.

Preoperative Resectability Estimates of Nonenhancing Glioma by Neurosurgeons and a Resection Probability Map.

Hendriks EJ, Idema S, Hervey-Jumper SL, Bernat AL, Zwinderman AH, Barkhof F, Vandertop WP, Mandonnet E, Duffau H, Berger MS, De Witt Hamer PC.

Neurosurgery. 2019 Aug 1;85(2):E304-E313. doi: 10.1093/neuros/nyy487.

PMID:
30423155
19.

Perioperative outcomes following reoperation for recurrent insular gliomas.

Morshed RA, Young JS, Han SJ, Hervey-Jumper SL, Berger MS.

J Neurosurg. 2018 Sep 1:1-7. doi: 10.3171/2018.4.JNS18375. [Epub ahead of print]

PMID:
30239317
20.

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.

Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M.

J Neurooncol. 2018 Nov;140(2):477-483. doi: 10.1007/s11060-018-2977-3. Epub 2018 Aug 27.

PMID:
30151703
21.

Subcortical stimulation mapping of descending motor pathways for perirolandic gliomas: assessment of morbidity and functional outcome in 702 cases.

Han SJ, Morshed RA, Troncon I, Jordan KM, Henry RG, Hervey-Jumper SL, Berger MS.

J Neurosurg. 2018 Aug 1:1-8. doi: 10.3171/2018.3.JNS172494. [Epub ahead of print]

PMID:
30117770
22.

5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas.

Chohan MO, Berger MS.

J Neurooncol. 2019 Feb;141(3):517-522. doi: 10.1007/s11060-018-2956-8. Epub 2018 Aug 10. Review.

PMID:
30097823
23.

Interfacility neurosurgical transfers: an analysis of nontraumatic inpatient and emergency department transfers with implications for improvements in care.

Safaee MM, Morshed RA, Spatz J, Sankaran S, Berger MS, Aghi MK.

J Neurosurg. 2018 Jul 1:1-9. doi: 10.3171/2018.3.JNS173224. [Epub ahead of print]

PMID:
30074453
24.

The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.

Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, Perry A, Shieh JTC, Solomon DA.

Brain Pathol. 2019 Jan;29(1):85-96. doi: 10.1111/bpa.12639. Epub 2018 Nov 6.

PMID:
30051528
25.

Disparities in health care determine prognosis in newly diagnosed glioblastoma.

Chandra A, Rick JW, Dalle Ore C, Lau D, Nguyen AT, Carrera D, Bonte A, Molinaro AM, Theodosopoulos PV, McDermott MW, Berger MS, Aghi MK.

Neurosurg Focus. 2018 Jun;44(6):E16. doi: 10.3171/2018.3.FOCUS1852.

26.

Safety and outcomes of resection of butterfly glioblastoma.

Dayani F, Young JS, Bonte A, Chang EF, Theodosopoulos P, McDermott MW, Berger MS, Aghi MK.

Neurosurg Focus. 2018 Jun;44(6):E4. doi: 10.3171/2018.3.FOCUS1857.

PMID:
29852771
27.

Cost-effectiveness development for the postoperative care of craniotomy patients: a safe transitions pathway in neurological surgery.

Osorio JA, Safaee MM, Viner J, Sankaran S, Imershein S, Adigun E, Weigel G, Berger MS, McDermott MW.

Neurosurg Focus. 2018 May;44(5):E19. doi: 10.3171/2018.2.FOCUS1812.

PMID:
29712529
28.

The transcortical equatorial approach for gliomas of the mesial temporal lobe: techniques and functional outcomes.

Morshed RA, Young JS, Han SJ, Hervey-Jumper SL, Berger MS.

J Neurosurg. 2019 Mar 1;130(3):822-830. doi: 10.3171/2017.10.JNS172055.

PMID:
29676697
29.

Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin.

Drusco A, Fadda P, Nigita G, Fassan M, Bottoni A, Gardiman MP, Sacchi D, Calore F, Carosi M, Antenucci A, Casini B, Kelani H, Pescarmona E, Di Leva G, Zanesi N, Berger MS, Croce CM.

EBioMedicine. 2018 Apr;30:105-112. doi: 10.1016/j.ebiom.2018.03.022. Epub 2018 Mar 21.

30.

Tuberculum sellae meningiomas: grading scale to assess surgical outcomes using the transcranial versus transsphenoidal approach.

Magill ST, Morshed RA, Lucas CG, Aghi MK, Theodosopoulos PV, Berger MS, de Divitiis O, Solari D, Cappabianca P, Cavallo LM, McDermott MW.

Neurosurg Focus. 2018 Apr;44(4):E9. doi: 10.3171/2018.1.FOCUS17753.

PMID:
29606045
31.

Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.

Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR.

Cell Rep. 2018 Mar 27;22(13):3672-3683. doi: 10.1016/j.celrep.2018.03.013.

32.

Postoperative Delirium in Glioblastoma Patients: Risk Factors and Prognostic Implications.

Flanigan PM, Jahangiri A, Weinstein D, Dayani F, Chandra A, Kanungo I, Choi S, Sankaran S, Molinaro AM, McDermott MW, Berger MS, Aghi MK.

Neurosurgery. 2018 Dec 1;83(6):1161-1172. doi: 10.1093/neuros/nyx606.

PMID:
29462362
33.

Region specific knock-out reveals distinct roles of chromatin modifiers in adult neurogenic niches.

Rhodes CT, Zunino G, Huang SA, Cardona SM, Cardona AE, Berger MS, Lemmon VP, Lin CA.

Cell Cycle. 2018;17(3):377-389. doi: 10.1080/15384101.2018.1426417. Epub 2018 Feb 19.

34.

Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma.

Ilkhanizadeh S, Sabelström H, Miroshnikova YA, Frantz A, Zhu W, Idilli A, Lakins JN, Schmidt C, Quigley DA, Fenster T, Yuan E, Trzeciak JR, Saxena S, Lindberg OR, Mouw JK, Burdick JA, Magnitsky S, Berger MS, Phillips JJ, Arosio D, Sun D, Weaver VM, Weiss WA, Persson AI.

Mol Cancer Res. 2018 May;16(5):777-790. doi: 10.1158/1541-7786.MCR-17-0413. Epub 2018 Feb 5.

35.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2018 Jan 8;33(1):152. doi: 10.1016/j.ccell.2017.12.012. No abstract available.

36.

A cross-sectional study of neurosurgical department chairs in the United States.

Flanigan PM, Jahangiri A, Golubovsky JL, Karnuta JM, May FJ, Berger MS, Aghi MK.

J Neurosurg. 2018 Nov 1;129(5):1342-1348. doi: 10.3171/2017.7.JNS17567.

PMID:
29303441
37.

Resection of primary motor cortex tumors: feasibility and surgical outcomes.

Magill ST, Han SJ, Li J, Berger MS.

J Neurosurg. 2018 Oct;129(4):961-972. doi: 10.3171/2017.5.JNS163045. Epub 2017 Dec 8.

PMID:
29219753
38.

Surgical oncology for gliomas: the state of the art.

Sanai N, Berger MS.

Nat Rev Clin Oncol. 2018 Feb;15(2):112-125. doi: 10.1038/nrclinonc.2017.171. Epub 2017 Nov 21. Review.

PMID:
29158591
39.

Seizure Outcome After Surgical Resection of Insular Glioma.

Wang DD, Deng H, Hervey-Jumper SL, Molinaro AA, Chang EF, Berger MS.

Neurosurgery. 2018 Oct 1;83(4):709-718. doi: 10.1093/neuros/nyx486.

PMID:
29126238
40.

Resection of gliomas deemed inoperable by neurosurgeons based on preoperative imaging studies.

Southwell DG, Birk HS, Han SJ, Li J, Sall JW, Berger MS.

J Neurosurg. 2018 Sep;129(3):567-575. doi: 10.3171/2017.5.JNS17166. Epub 2017 Nov 10.

PMID:
29125414
41.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

42.

Connected speech in transient aphasias after left hemisphere resective surgery.

McCarron A, Chavez A, Babiak M, Berger MS, Chang EF, Wilson SM.

Aphasiology. 2017;31(11):1266-1281. doi: 10.1080/02687038.2017.1278740. Epub 2017 Jan 17.

43.

In Reply: Neurosurgical Education in a Changing Healthcare and Regulatory Environment: A Consensus Statement From 6 Programs.

Kim DH, Dacey RG, Zipfel GJ, Berger MS, McDermott M, Barbaro NM, Shapiro SA, Solomon RA, Harbaugh R, Day AL.

Neurosurgery. 2017 Oct 1;81(4):E47. doi: 10.1093/neuros/nyx348. No abstract available.

PMID:
28934443
44.

Management of Elderly Patients with Glioblastoma after CE.6.

Das S, Kim AH, Chang S, Berger MS.

Front Oncol. 2017 Aug 30;7:196. doi: 10.3389/fonc.2017.00196. eCollection 2017. No abstract available.

45.

Changing Operating Room Culture: Implementation of a Postoperative Debrief and Improved Safety Culture.

Magill ST, Wang DD, Rutledge WC, Lau D, Berger MS, Sankaran S, Lau CY, Imershein SG.

World Neurosurg. 2017 Nov;107:597-603. doi: 10.1016/j.wneu.2017.08.090. Epub 2017 Aug 24.

PMID:
28843757
46.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

47.

Intraoperative perception and estimates on extent of resection during awake glioma surgery: overcoming the learning curve.

Lau D, Hervey-Jumper SL, Han SJ, Berger MS.

J Neurosurg. 2018 May;128(5):1410-1418. doi: 10.3171/2017.1.JNS161811. Epub 2017 Jul 21.

PMID:
28731401
48.

Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history.

Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA.

Clin Neuropathol. 2017 Sep/Oct;36(5):213-221. doi: 10.5414/NP301022.

49.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):152.

50.

Wavelength-specific lighted suction instrument for 5-aminolevulinic acid fluorescence-guided resection of deep-seated malignant glioma: technical note.

Morshed RA, Han SJ, Lau D, Berger MS.

J Neurosurg. 2018 May;128(5):1448-1453. doi: 10.3171/2017.1.JNS161949. Epub 2017 Jun 30.

PMID:
28665248

Supplemental Content

Loading ...
Support Center